AI-GF-GNW on Prolonged Grief Reactions
AI-Assisted Grief-Focused Guided Narrative Writing for Subclinical Prolonged Grief Disorder in Bereaved Chinese Adolescents: A Three-Arm Parallel Randomized Controlled Trial.
Prolonged Grief Disorder (PGD) is a severe, disabling condition characterized by intense yearning and difficulty accepting the reality of loss, which significantly impairs the academic and psychosocial functioning of bereaved adolescents. While Grief-Focused Cognitive Behavioral Therapy (GF-CBT) is effective, its high cost and resource-intensive nature limit its accessibility for adolescents in mainland China. Grief-Focused Guided Narrative Writing (GF-GNW) offers a scalable, low-cost alternative that facilitates memory integration.
Furthermore, integrating Artificial Intelligence (AI) to provide personalized, structured feedback has the potential to simulate therapist functions and enhance intervention efficacy. However, the specific efficacy of AI-assisted feedback in this context remains empirically unvalidated.
This parallel randomized controlled trial aims to examine the effectiveness of AI-assisted GF-GNW (AI-GF-GNW) in treating Chinese adolescents (aged 10-19) with subclinical PGD, compared to a no-feedback NF-GF-GNW group and a free writing group. Primary outcomes include PGD symptom severity, while secondary outcomes assess depression, anxiety, and daily functioning. We hypothesize that both active intervention arms will significantly alleviate PGD and related symptoms compared to the free writing group, and that the AI-GF-GNW group will demonstrate a significantly greater reduction in symptoms and functional impairment than the NF-GF-GNW group.
調査の概要
状態
研究の種類
入学 (推定)
段階
- 適用できない
連絡先と場所
研究連絡先
- 名前：Yinyin Zang, PhD
- 電話番号：+86-010-62756953
- メール：yinyin.zang@pku.edu.cn
研究場所
-
-
Beijing Municipality
-
Beijing、Beijing Municipality、中国
- Peking University
-
-
参加基準
適格基準
就学可能な年齢
- 子
- 大人
健康ボランティアの受け入れ
説明
Inclusion Criteria:
- Junior and senior high school students currently studying in Chinese Mainland, aged 10-19;
- Between 6 and 60 months prior to the experimental period, experienced the death of a significant family member or close friend or close friend;
- The total symptom score of PG-13-R is between 20-29 points;
- Ability to write and understand written guidelines, to use the mobile phone to interact with AI;
- Consent to participate in the study.
Exclusion Criteria:
- Diagnosed or previously diagnosed with mental illness
- The bereavement time does not meet the time window
- PG-13-R score is not within the range
- At present, there is suicidal ideation or recent severe self harm behavior (Reynolds' Suicidal Ideation Questionnaire, SIQ-JR-4>0), and a crisis intervention hotline is provided when necessary.
- Has received other grief counseling or is currently taking psychiatric medication within the past month
研究計画
研究はどのように設計されていますか？
デザインの詳細
- 主な目的：処理
- 割り当て：ランダム化
- 介入モデル：並列代入
- マスキング：トリプル
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的：AI-GF-GNW
|
Participants will independently complete the intervention writing tasks via the H5 platform.
Participants were required to complete a 6-day, 3-session narrative writing task.
Each session requires more than 20 minutes of uninterrupted writing.
Session 1 requires describing the specific details and feelings of the bereavement event; Session 2 requires describing the negative impact of the event and one's own negative feelings; Session 3 requires a description of the positive impact of the event and one's own positive feelings, with a one-day interval between each session, synchronized with the NF-GF-GNW group.
When participants complete and submit their writing, they will immediately receive a response generated by the AI large language model.
Participants are not allowed to engage in any additional interaction with the AI large language model other than submitting writing content and receiving feedback.
|
|
実験的：NF-GF-GNW
|
All processes are the same as the AI-GF-GNW group, except that when participants complete their writing and submit, the platform will only display a "submission successful" prompt and will not provide any feedback on the writing content.
|
|
アクティブコンパレータ：FWG
|
Participants in the FWG will not receive structured guidance, and are only required to write freely about their loss experiences.
The writing sessions will follow the same schedule and duration as the other groups.
|
この研究は何を測定していますか？
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Prolonged Grief Disorder-13-Revision (PG-13-R)
時間枠：Baseline (0 Day), post-treatment assessment (5 Day), follow-up assessment (35 Day)
|
PG-13-R is a standardized diagnostic tool designed to assess the severity of prolonged grief disorder symptoms over the past month.
The instrument consists of 10 questions scored on a 5-point Likert scale, alongside 2 true/false questions and 1 open-ended question assessing functional impairment and duration.Who gets 30 points or higher will be considered as clinical prolonged grief reactions.
|
Baseline (0 Day), post-treatment assessment (5 Day), follow-up assessment (35 Day)
|
|
Patient Health Questionnaire (PHQ-9)
時間枠：Baseline (0 Day), post-treatment assessment (5 Day), follow-up assessment (35 Day)
|
PHQ-9 is a brief, validated screening tool used to measure the severity of depression symptoms in adolescents over the past two weeks.
9 questions are scored on a Likert scale of 0-3 with 0 being not at all and 3 being nearly every day.
|
Baseline (0 Day), post-treatment assessment (5 Day), follow-up assessment (35 Day)
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Generalized Anxiety Disorder (GAD-7)
時間枠：Baseline (0 Day), post-treatment assessment (5 Day), follow-up assessment (35 Day)
|
GAD-7 is an easy-to-perform initial screening tool for generalized anxiety disorder.
Questions are scored on a Likert scale of 0-3 with 0 being not at all and 3 being nearly every day.
|
Baseline (0 Day), post-treatment assessment (5 Day), follow-up assessment (35 Day)
|
|
WHO Disability Assessment Schedule-short version(WHODAS 2.0)
時間枠：Baseline (0 Day), post-treatment assessment (5 Day), follow-up assessment (35 Day)
|
WHODAS 2.0 is a comprehensive instrument developed by the World Health Organization to measure health status and functional disability across six core domains over the past 30 days.
12 questions are scored on a Likert scale of 1-5 with 1 being no difficulty and 5 being extreme difficulty.
|
Baseline (0 Day), post-treatment assessment (5 Day), follow-up assessment (35 Day)
|
協力者と研究者
スポンサー
研究記録日
主要日程の研究
研究開始 (推定)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。